![CROI 2013: Functional Cure of HIV-infected Infant after Early ART [VIDEO]](/images/resized/images/conf-photos/CROI2013/persaud-interview-img_3293-rect-500_330_228.jpg)
UNAIDS: More than 7 Million Africans on HIV Treatment, Deaths Continue to Fall
The number of people in Africa receiving antiretroviral medications increased from less than 1 million in 2005 to an estimated 7.1 million in 2012, according to a new report from UNAIDS. The report also notes that AIDS-related deaths and new HIV infections have both fallen by about 30% over the past decade. 
Coverage of the 2013 EASL International Liver Congress
HIVandHepatitis.com coverage of the 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) in Amsterdam, April 24-28, 2013.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, and prevention and treatment of hepatocellular carcinoma.
4/27/13
EASL 2013: Direct-acting Antivirals Boost Response to Pegylated Interferon/Ribavirin
For people with chronic hepatitis C who cannot wait for all-oral regimens, interferon-based therapy is still a reality. Researchers at the recent EASL International Liver Congress (EASL 2013) presented promising data showing that several experimental direct-acting antiviral agents (DAAs) can significantly improve response rates without reducing tolerability.
Coverage of the 2013 Conference on Retroviruses and Opportunistic Infections
HIVandHepatitis.com coverage of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), March 3-6, 2013, in Atlanta.
Conference highlights include experimental therapies for HIV and hepatitis C, HIV cure research, aging, HIV-related conditions and treatment complications, HIV treatment as prevention and PrEP, and HIV/HBV and HIV/HCV coinfection.
HIVandHepatitis.com CROI 2013 conference section
Web Design and Development by